Limits...
A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease.

Holmes MV, Frikke-Schmidt R, Melis D, Luben R, Asselbergs FW, Boer JM, Cooper J, Palmen J, Horvat P, Engmann J, Li KW, Onland-Moret NC, Hofker MH, Kumari M, Keating BJ, Hubacek JA, Adamkova V, Kubinova R, Bobak M, Khaw KT, Nordestgaard BG, Wareham N, Humphries SE, Langenberg C, Tybjaerg-Hansen A, Talmud PJ - Atherosclerosis (2014)

Bottom Line: In total 13 studies (including unpublished data from eight cohorts) with 10,134 CHD events in 130,004 individuals of European descent were identified.When the association between APOE genotype and CHD was stratified by smoking status, compared to non-ε4 carriers, ε4 carriers had an OR of 1.11 (95%CI: 1.02, 1.21) in 28,789 present smokers and an OR of 1.04 (95%CI 0.98, 1.10) in 101,215 previous/never smokers, with no evidence of effect modification (P-value for heterogeneity = 0.19).Analysis of pack years in individual participant data of >60,000 with adjustment for cardiovascular traits also failed to identify evidence of effect modification.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Division of Transplantation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Epidemiology & Public Health, University College London, London, UK. Electronic address: mvholmes@gmail.com.

Show MeSH

Related in: MedlinePlus

Association between APOE genotype and CHD in all individuals and stratified by smoking status. P-value for heterogeneity obtained from testing whether an interaction term between APOE and smoking represents the data better than no interaction term (tested using likelihood ratio test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4232362&req=5

fig1: Association between APOE genotype and CHD in all individuals and stratified by smoking status. P-value for heterogeneity obtained from testing whether an interaction term between APOE and smoking represents the data better than no interaction term (tested using likelihood ratio test).

Mentions: When tested formally using likelihood ratio test, we identified no evidence of an interaction between APOE genotype and smoking (Parameter estimate = 0.07; 95%CI: −0.03, 0.17; χ2 1.72; (df = 1); P = 0.19) (Fig. 1).


A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease.

Holmes MV, Frikke-Schmidt R, Melis D, Luben R, Asselbergs FW, Boer JM, Cooper J, Palmen J, Horvat P, Engmann J, Li KW, Onland-Moret NC, Hofker MH, Kumari M, Keating BJ, Hubacek JA, Adamkova V, Kubinova R, Bobak M, Khaw KT, Nordestgaard BG, Wareham N, Humphries SE, Langenberg C, Tybjaerg-Hansen A, Talmud PJ - Atherosclerosis (2014)

Association between APOE genotype and CHD in all individuals and stratified by smoking status. P-value for heterogeneity obtained from testing whether an interaction term between APOE and smoking represents the data better than no interaction term (tested using likelihood ratio test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4232362&req=5

fig1: Association between APOE genotype and CHD in all individuals and stratified by smoking status. P-value for heterogeneity obtained from testing whether an interaction term between APOE and smoking represents the data better than no interaction term (tested using likelihood ratio test).
Mentions: When tested formally using likelihood ratio test, we identified no evidence of an interaction between APOE genotype and smoking (Parameter estimate = 0.07; 95%CI: −0.03, 0.17; χ2 1.72; (df = 1); P = 0.19) (Fig. 1).

Bottom Line: In total 13 studies (including unpublished data from eight cohorts) with 10,134 CHD events in 130,004 individuals of European descent were identified.When the association between APOE genotype and CHD was stratified by smoking status, compared to non-ε4 carriers, ε4 carriers had an OR of 1.11 (95%CI: 1.02, 1.21) in 28,789 present smokers and an OR of 1.04 (95%CI 0.98, 1.10) in 101,215 previous/never smokers, with no evidence of effect modification (P-value for heterogeneity = 0.19).Analysis of pack years in individual participant data of >60,000 with adjustment for cardiovascular traits also failed to identify evidence of effect modification.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Division of Transplantation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Epidemiology & Public Health, University College London, London, UK. Electronic address: mvholmes@gmail.com.

Show MeSH
Related in: MedlinePlus